Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 55

PanChol vaccine safety study in healthy adults

Official title: Safety and Immunogenicity of PanChol, a Novel Live Attenuated Oral Cholera Vaccine, in Zambia Adults

Run by Centre for Infectious Disease Research in Zambia · NCT07107516 · Data updated 2026-11-12

This study tests whether the PanChol oral cholera vaccine is safe and what kind of immune response it provokes in healthy adults aged 18 to 55.

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 55 Years
SexAll
Enrollment32 (estimated)
SponsorCentre for Infectious Disease Research in Zambia
Academic / other
Locations1 site (Lusaka, Lusaka Province)
StatusRecruiting
StartedMay 20, 2026
Main results expectedNovember 30, 2026
Study endsJanuary 31, 2027
Registry record updatedOctober 6, 2026
Trial IDNCT07107516 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults aged 18-55 who can provide informed consent and comply with inpatient and follow-up procedures.

Probably not a fit

Participants with no immune response or significant adverse events may not experience direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1b trial will compare PanChol to placebo to assess safety and immune response after vaccination. Adults aged 18-55 will be admitted for inpatient monitoring until vaccine-related stool shedding stops, with follow-up visits at 1, 2, and 3 months after discharge and an optional 4th month visit. The study will record adverse events and laboratory measures, helping to establish tolerability and preliminary immunogenicity. It is sponsored by CIDRZ with activities at the CIDRZ Matero site in Lusaka, Zambia.

Why it matters

Potential benefit: If successful, PanChol could become a safer or more effective option for cholera prevention.

How similar studies have gone: Previous cholera vaccine trials have explored safety and immunogenicity, but this study uses a new PanChol formulation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Must have given written informed consent (signed and dated) and any other authorizations required by local law and be able to comply with all study requirements.
2. Healthy adults aged from 18 to 55 years old.
3. Considered healthy, as judged by the clinical investigator, according to medical history, physical examination, vital signs, screening laboratories, and medication history.
4. Capable of understanding, consenting, and complying with the entire study protocol including the inpatient period.
5. Female participants must be non-pregnant and non-lactating and either

   1. surgically sterile (history of bilateral ligation, bilateral salpingectomy, bilateral oophorectomy, total hysterectomy) or postmenopausal (defined as amenorrhea for at least 12 consecutive months before screening without an alternative medical cause)
   2. be of child-bearing potential and practicing an acceptable method of contraception or abstaining from all activities that could result in pregnancy for at least 28 days before vaccination until 3 months after receiving the investigational product.

Acceptable methods of contraception include barrier methods (such as condom, diaphragm, or cervical cap used in conjunction with spermicide), intrauterine device, hormonal contraception (that may be taken or administered by oral, intravaginal, transdermal, subdermal or IM route), vasectomized partner (the vasectomized partner should be the sole partner for that participant)

Exclusion Criteria:

1. Confirmed or suspected immunosuppressive condition, as a result of a disease (e.g., primary immune deficiency, malignancy, HIV infection) or have taken any systemic immunosuppressive therapy within 6 months of enrollment.
2. Pregnant or lactating women.
3. History of gastrointestinal (GI) disorder, such as previous major GI surgery, malabsorption, or any chronic GI disorders that would interfere, according to the investigator, with the IP.
4. Acute GI or febrile illness within 7 days of enrollment.
5. Have any acute or chronic medical condition that, in the opinion of the investigator, would make vaccination unsafe or interfere with the evaluation of immune response to study vaccination.
6. History of cholera vaccination.
7. History of cholera infection.
8. Abnormal stool pattern, defined as \< 3 or \>21 stools per week.
9. Allergy or intolerance to PanChol or placebo component (sodium bicarbonate, lactose, ascorbic acid)
10. Use of any systemic antibiotics within 1 month of PanChol administration.
11. Receipt of a live vaccine in the previous 4 weeks or planned in the 4 weeks following enrollment.
12. Receipt of a killed or subunit (non-live) vaccine in the previous 2 weeks or planned in the 2 weeks following enrollment.
13. Individuals who do not speak English
14. Childcare workers with direct contact with children ≤ 2 years of age
15. Individuals whose occupation involves handling of food
16. Healthcare workers who have direct contact with patients who are immunodeficient, HIV-positive, or have an unstable medical condition
17. Use laxatives regularly
18. Have diarrhea within 48 hours before enrollment
19. Have a history of hypersensitivity to any of the tetracyclines
20. Have a history of hypersensitivity to streptomycin or any aminoglycoside due to the known cross-sensitivity of patients to drugs in this class.
21. Individuals who have a household member who are immunodeficient, HIV-positive, or have an unstable medical condition.

Where it's running

  • CIDRZ Matero clinical reseach site
    Lusaka, Lusaka Province, Zambia
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.